ClinicalTrials.gg
CompletedNCT05333406Updated Feb 17, 2023

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

A Phase 1 interventional study of EN001 and EN001 in Charcot-Marie-Tooth Disease, Type IA, sponsored by ENCell. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by ENCell · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Charcot-Marie-Tooth disease (CMT) type 1A

Read the detailed description

It is the first in human (FIH), 3+3 design clinical trial to evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A.

02

Conditions studied

  • Charcot-Marie-Tooth Disease, Type IA
03

In context

Charcot-Marie-Tooth Disease

114 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 38 are open to participants now.

This study's enrollment of 9 is below the median of 41 across 62 interventional studies indexed under Charcot-Marie-Tooth Disease.

Browse Charcot-Marie-Tooth Disease studies →

Lead sponsor

ENCell is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 19 to 75 years old
  2. Those diagnosed with CMT type 1A by a genetic test
  3. Those whose CMTNS-v2 score is more than 2 and 20 or fewer points, and the severity of the disease is mild to moderate
  4. Those who have dorsiflexion muscle weakness
  5. Those who can comply with the requirements for clinical trials
  6. For women of , those who have a negative urine pregnancy test at screening
  7. Those who use a medically acceptable method of until clinical trial visit 7 (short-term follow-up visit, 16 weeks): hormonal contraception, intrauterine device (IUD), intrauterine system (IUS), vasectomy, tubal ligation, or double barrier method using a cervical cap or a diaphragm with a male condom.
  8. Those who voluntarily agree to participate in this study and sign an IRB-approved consent form after being informed about the characteristics of this clinical trial prior to all screening tests

Exclusion criteria

Exclusion Criteria:

  1. Those with other neuromuscular diseases that the investigator judges cannot participate in the clinical trial
  2. Patients diagnosed with type 1 or type 2 diabetes
  3. Those with a history of stroke or cerebral ischemic attack within 12 months of screening
  4. Those with a history of coronary artery diseases such as myocardial infarction or unstable angina within 12 months of screening
  5. Those who have undergone orthopedic surgery on the lower extremities (bone and ligament correction, artificial joint insertion, osteotomy, arthroscopic surgery) within 6 months of screening
  6. Those who have ankle contractures or have surgery that may affect muscle strength assessment
  7. Those who have experience with stem cell therapy or gene therapy before screening
  8. Those who have participated in clinical trials for chemical synthetic drugs before screening (except when 5 times the half-life has passed)
  9. Patients with uncontrolled hypertension (If the systolic blood pressure is 180 mmHg or higher or the diastolic blood pressure is 110 mmHg or higher)
  10. If there is a history of malignant tumors other than basal cell carcinoma or squamous cell carcinoma occurring in the skin within 5 years of screening
  11. Those who diagnosed with active pulmonary tuberculosis
  12. patients who are taking immunosuppressants, chemotherapy, radiation therapy, etc.
  13. Mental illness patients
  14. Those who are pregnant or lactating
  15. Those with significant heart, lung, liver, kidney, hematological, immunological, behavioral disease, or other diseases including malignant tumors
  16. Those who have a previous or current medical condition that may adversely affect the safety of the subject, make it difficult to complete treatment or affect the evaluation of clinical trial results at the discretion of the investigator
  17. Those who do not have the will or ability to comply with clinical trial procedures at the discretion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Dose group A (Low dose)

    Participants will receive EN001 intravenously (IV) once on Day 0.

    Drug: EN001

  • Experimental
    Dose group B (High dose)

    Participants will receive EN001 intravenously (IV) once on Day 0.

    Drug: EN001

Interventions

  • DrugEN001

    EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows. Dose group A (Low dose): 5.0x10\^5 cells/kg

    Also known as: EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)

  • DrugEN001

    EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows. Dose group B (High dose): 2.5x10\^6 cells/kg

    Also known as: EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)

06

What researchers measure

Primary outcomes

  1. Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product

    Number of participants with treatment-related AEs/SAEs as assessed by CTCAE v5.0

    Time frame: Week 16 after treatment

  2. Determination of Dose-limiting toxicity (DLT) levels of EN001

    Among the adverse events occurring for 4 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE v5.0

    Time frame: Up to Week 4 after dosing on Day 0

  3. Determination of Maximum tolerated dose (MTD) levels of EN001

    Among the adverse events occurring for 4 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE v5.0 Maximum tolerated dose defines the evaluated maximum dose level in which greater than two participants of six participants experience Dose-limiting toxicity (DLT) under the dose level. The dose level where two participants of six participants experience DLT will be the maximum tolerated dose.

    Time frame: Up to Week 4 after dosing on Day 0

  4. Number of participants with Vital Signs abnormalities

    Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. The number of participants with at least one potentially clinically significant abnormal vital sign finding were reported as treatment emergent adverse events (TEAEs).

    Time frame: From screening up to Week 16

  5. Number of participants with clinically significant abnormalities of Physical Examinations

    Physical Examinations include general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. Number of participants with potentially clinically significant abnormalities in physical examinations were reported as TEAEs.

    Time frame: From screening up to Week 16

  6. Number of participants with abnormalities of Laboratory Parameters

    Laboratory Parameters include hematology, chemistry laboratory tests, urinalysis, coagulation test and plasma viral load test and will be assessed by CTCAE 5.0 to evaluate safety and tolerability of EN001. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs.

    Time frame: From screening up to Week 16

  7. Number of participants with 12-lead Electrocardiography (ECG) abnormalities

    Measured by result of the ECG measurements and findings

    Time frame: From screening to baseline on Day 1 (Predose to end of infusion and 90 min after completion of infusion)

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Occurrence of any adverse reactions, development of new blood clots, tumors, immune responses (like autoimmune reactions) and death, and/or serious adverse events related investigational product will be summarized by actual treatment groups respectively.

    Time frame: From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

  2. Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters

    Abnormalities of Vital Signs, Physical Findings, and Laboratory parameters (as described above) will be collected and analyzed, and then assessed by CTCAE 5.0 to evaluate the long-term safety of EN001.

    Time frame: From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

  3. Change from baseline in disease severity CMTNS-v2 score

    Disease severity measured by CMTNS-v2 score will be collected and analyzed to evaluate the exploratory efficacy of EN001.

    Time frame: Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)

  4. Change from baseline in gait and balance functions

    Gait and balance functions measured by Ten Meter Walking Test(10MWT), Functional Disability Scale (FDS), and Overall Neuropathy Limitation Score (ONLS) leg scale will be collected and analyzed to evaluate the exploratory efficacy of EN001.

    Time frame: Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)

  5. Change from baseline in the degree of muscle damage (%)

    The degree of muscle damage measured by lower extremity magnetic resonance imaging (MRI) scan will be collected and analyzed to evaluate the exploratory efficacy of EN001.

    Time frame: Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)

  6. Change from baseline in nerve regeneration potential

    Nerve generation potential measured by MNCV, SNCV, CMAP, and SNAP will be collected and analyzed to evaluate the exploratory efficacy of EN001.

    Time frame: Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Dec 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Apr 19, 2022
StartActual
Feb 22, 2022
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Last update
Feb 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05333406
Lead sponsor
ENCell
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Feb 22, 2022
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Last update
Feb 17, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EN001

Start the discussion